Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V. Liu, Leora Horn, Makoto Nishio et al.|Journal of Clinical Oncology|2021Cited by 818
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLCByoung Chul Cho, Patricia Lorenzini, Shun Lu et al.|New England Journal of Medicine|2024Cited by 369
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAEnriqueta Felip, S.-H. Lee, Byoung Chul Cho et al.|Annals of Oncology|2024Cited by 81
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Stephen V. Liu, Rafał Dziadziuszko et al.|Lung Cancer|2024Cited by 66
Editorial BoardRolf A. Stahel, Giuseppe Curigliano, Andrés Cervantes et al.|Cancer Treatment Reviews|2023Cited by 0